Lupin, which is pivoting from a pure-play generics player to an increasing mix of complex generics, specialty medicines and biosimilars, reported net profit that jumped by nearly 50% in the first quarter from a year earlier. The rise was thanks to robust US revenues powered mainly by spill-over from the 180-day exclusivity period for anti-angina drug ranolazine, a generic of Ranexa.
The strong earnings, though, were overshadowed by analysts’ concerns about slow US scale-ups of Solosec (secnidazole), an antimicrobial agent against...
